Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Application of MRI Quantitative Parameters in Identifying Myelosuppression Risk of Neoadjuvant Chemoradiotherapy for Rectal Cancer

NCT04970498 is registered in ClinicalTrials.gov with Peking University Third Hospital as lead sponsor.

NCT NCT04970498
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04970498 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Application of MRI Quantitative Parameters in Identifying Myelosuppression Risk of Neoadjuvant Chemoradiotherapy for Rectal Cancer
Lead sponsor
Peking University Third Hospital
Phase
Observational
Overall status
Unknown status
Start date
February 1, 2021
Completion date
October 31, 2022
Enrollment
120 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

rectal cancer stage ii, rectal cancer stage iii